Application of the T cell product
As this study aimed at prevention and pre-emptive treatment of reactivation of CMV and EBV the dose schedule was planned to start as early as day 30 post aSCT. A total of 3 equal doses was planned for each patient with consecutive doses on days 30, 60, and 90 while patients were still receiving cyclosporine A. The targeted cell dose was 50,000 CD3+ T cells/kg body weight. On average, the cell number per dose administered to patients was 29,882 ± 5,883 CD3+ T cells/kg BW (Application of the T cell product. 